Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Apr;45(4):412-5.
doi: 10.1046/j.1365-2125.1998.t01-1-00704.x.

Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients

C Brefel  1 , C Thalamas, S Rayet, A Lopez-Gil, K Fitzpatrick, S Bullman, D R Citerone, A C Taylor, J L Montastruc, O Rascol
Affiliations
Clinical Trial

Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients

C Brefel et al. Br J Clin Pharmacol. 1998 Apr.

Abstract

Aims: Ropinirole is a specific non-ergoline dopamine D2-receptor agonist with antiparkinsonian properties. The pharmacokinetic parameters of ropinirole taken in the fasted condition were compared with those when it was co-administered with food.

Methods: This was an open, randomized, two sessions cross over study in 12 patients with Parkinson's disease, comparing the steady-state pharmacokinetic profiles of ropinirole on two different study days: 'fasted' and 'fed'.

Results: The mean Cmax was lower in the 'fed' regimen than in the 'fasted' one (-25%, P=0.002). The median tmax was observed 2.6 h later in the 'fed' regimen than in the 'fasted' regimen (P<0.05). There was a slight but significant decrease in AUC(0,8 h) in the 'fed' regimen (P=0.03).

Conclusions: Food decreases the rate of absorption of ropinirole, but has little effect on the extent of absorption.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma ropinirole concentrations during the ‘fed’ (○) and ‘fasted’ (•) sessions. Values are means±s.d. for 12 patients.
See this image and copyright information in PMC

References

    1. Neuvonen PJ, Kivistö KT. The clinical significance of food-drug interactions: a review. Med J Aust. 1989;150:36–40. - PubMed
    1. Frankel JP, Kempster PA, Bovingdon M, Webster R, Lees AJ. The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry. 1989;52:1063–1067. - PMC - PubMed
    1. Vidaihlet M, Bonnet AM, Belal S, Dubois B, Marle C, Agid Y. Ropinirole without levodopa in Parkinson’s disease. Lancet. 1990;336:316–317. - PubMed
    1. Rascol O, Brooks D, Brunt E, Korczyn A, Poewe W, Stocchi F on behalf of the 056 Study Group. Ropinirole in the treatment of early Parkinson’s disease: a six month interim report of a five year L-dopa control study. Mov Disord. 1997 in press. - PubMed
    1. Kleedorfer B, Stern QM, Lees AJ. Ropinirole (SK and F 101468) in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1991;54:938. - PMC - PubMed

Publication types